Please enable JavaScript to continue using this application.

Compare $CRVS vs $KURA | Chartloom

Compare

$CRVS vs $KURA

Corvus Pharmaceuticals Inc · Kura Oncology Inc

CRVS

Corvus Pharmaceuticals Inc

KURA

Kura Oncology Inc

Compare $CRVS vs $KURA

Comparing Corvus Pharmaceuticals Inc and Kura Oncology Inc

CRVSCorvus Pharmaceuticals Inc

KURAKura Oncology Inc

CRVSCorvus Pharmaceuticals Inc

Market cap

$885M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

43.7%

52W performance

50.3%

FCF yield

-5.1%

KURAKura Oncology Inc

Market cap

$941M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.49x

Rev growth (TTM)

-7.3%

YTD performance

2.6%

52W performance

5.2%

FCF yield

-12.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRVS

KURA

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

KURA

Kura Oncology Inc

Market Cap

CRVS$885M

KURA$941M

Enterprise Value

CRVS$866M

KURA$881M

Price

CRVS$10.52

KURA$10.60

P/E Ratio

CRVSN/A

KURAN/A

P/S Ratio

CRVS0.00x

KURA12.18x

EV/Sales

CRVS0.00x

KURA11.40x

EV/EBITDA

CRVS0.00x

KURA0.00x

P/B Ratio

CRVS4.07x

KURA19.56x

P/FCF Ratio

CRVSN/A

KURAN/A

EV/FCF

CRVS-19.14x

KURA-7.50x

PEG Ratio

CRVSN/A

KURAN/A

Forward P/E (NTM)

CRVSN/A

KURAN/A

Forward P/S (NTM)

CRVSN/A

KURA6.49x

Revenue (TTM)

CRVS$0

KURA$77M

Revenue Growth (YoY)

CRVSN/A

KURA-7.3%

Forward Rev Growth

CRVS1220.6%

KURA106.3%

Gross Margin (TTM)

CRVS0.0%

KURA72.4%

Operating Margin (TTM)

CRVS0.0%

KURA0.0%

EBITDA Margin (TTM)

CRVS0.0%

KURA-410.2%

Net Margin (TTM)

CRVS0.0%

KURA-384.3%

FCF Margin (TTM)

CRVSN/A

KURA-152.1%

Net Income (TTM)

CRVS$-54M

KURA$-297M

FCF (TTM)

CRVS$-45M

KURA$-117M

EPS (TTM)

CRVS-$0.59

KURA-$3.34

ROE (TTM)

CRVS-3615.0%

KURA-20718.0%

ROA (TTM)

CRVS-3362.0%

KURA-4517.0%

ROIC (TTM)

CRVS-3615.0%

KURA-19400.0%

Cash

CRVS$19M

KURA$70M

Debt

CRVS$0

KURA$10M

Net Cash/Debt

CRVS$19M

KURA$60M

Current Ratio (TTM)

CRVS16.16x

KURA4.73x

Quick Ratio (TTM)

CRVS15.92x

KURA4.47x

Debt/Equity (TTM)

CRVS0.00x

KURA0.20x

Debt/Assets (TTM)

CRVS0.0%

KURA0.0%

Interest Coverage (TTM)

CRVSN/A

KURAN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

KURA0.00x

Beta

CRVS1.59

KURA0.53

52W Performance

CRVS50.3%

KURA5.2%

YTD Performance

CRVS43.7%

KURA2.6%

% from 52W High

CRVS-61.0%

KURA-23.7%

% from 52W Low

CRVS64.6%

KURA44.1%

Asset Turnover (TTM)

CRVS0.00x

KURA0.12x

FCF Yield (TTM)

CRVS-5.1%

KURA-12.5%

Earnings Yield (TTM)

CRVS-6.1%

KURA-31.5%

Dividend Yield (TTM)

CRVSN/A

KURAN/A

Rule of 40

CRVS0.0

KURA-159.3

EV/GP/RG

CRVSN/A

KURA0.09

Ticker research

View CRVS research View KURA research

Metric	CRVS Corvus Pharmaceuticals Inc	KURA Kura Oncology Inc
Market & Valuation
Market Cap	$885M	$941M
Enterprise Value	$866M	$881M
Price	$10.52	$10.60
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	12.18x
EV/Sales	0.00x	11.40x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.07x	19.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.14x	-7.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.49x
Revenue & Growth
Revenue (TTM)	$0	$77M
Revenue Growth (YoY)	N/A	-7.3%
Forward Rev Growth	1220.6%	106.3%
Profitability
Gross Margin (TTM)	0.0%	72.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-410.2%
Net Margin (TTM)	0.0%	-384.3%
FCF Margin (TTM)	N/A	-152.1%
Net Income (TTM)	$-54M	$-297M
FCF (TTM)	$-45M	$-117M
EPS (TTM)	-$0.59	-$3.34
ROE (TTM)	-3615.0%	-20718.0%
ROA (TTM)	-3362.0%	-4517.0%
ROIC (TTM)	-3615.0%	-19400.0%
Financial Health
Cash	$19M	$70M
Debt	$0	$10M
Net Cash/Debt	$19M	$60M
Current Ratio (TTM)	16.16x	4.73x
Quick Ratio (TTM)	15.92x	4.47x
Debt/Equity (TTM)	0.00x	0.20x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	0.53
52W Performance	50.3%	5.2%
YTD Performance	43.7%	2.6%
% from 52W High	-61.0%	-23.7%
% from 52W Low	64.6%	44.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.12x
FCF Yield (TTM)	-5.1%	-12.5%
Earnings Yield (TTM)	-6.1%	-31.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-159.3
EV/GP/RG	N/A	0.09
Ticker research	View CRVS research	View KURA research

Valuation

P/S Ratio

CRVS

0.00x

KURA

12.18x

EV/FCF

CRVS

-19.14x

KURA

-7.50x

Growth & revenue

Revenue Growth TTM

KURA

-7.3%

Forward Revenue Growth

CRVS

1220.6%

KURA

106.3%

Profitability & performance

Gross Margin

KURA

72.4%

CRVS

0.0%

ROE

CRVS

-3615.0%

KURA

-20718.0%

FCF Yield %

CRVS

-5.1%

KURA

-12.5%

52-Week Performance

CRVS

50.3%

KURA

5.2%

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

KURA

Kura Oncology Inc

Market Cap

CRVS$885M

KURA$941M

Enterprise Value

CRVS$866M

KURA$881M

Price

CRVS$10.52

KURA$10.60

P/E Ratio

CRVSN/A

KURAN/A

P/S Ratio

CRVS0.00x

KURA12.18x

EV/Sales

CRVS0.00x

KURA11.40x

EV/EBITDA

CRVS0.00x

KURA0.00x

P/B Ratio

CRVS4.07x

KURA19.56x

P/FCF Ratio

CRVSN/A

KURAN/A

EV/FCF

CRVS-19.14x

KURA-7.50x

PEG Ratio

CRVSN/A

KURAN/A

Forward P/E (NTM)

CRVSN/A

KURAN/A

Forward P/S (NTM)

CRVSN/A

KURA6.49x

Revenue (TTM)

CRVS$0

KURA$77M

Revenue Growth (YoY)

CRVSN/A

KURA-7.3%

Forward Rev Growth

CRVS1220.6%

KURA106.3%

Gross Margin (TTM)

CRVS0.0%

KURA72.4%

Operating Margin (TTM)

CRVS0.0%

KURA0.0%

EBITDA Margin (TTM)

CRVS0.0%

KURA-410.2%

Net Margin (TTM)

CRVS0.0%

KURA-384.3%

FCF Margin (TTM)

CRVSN/A

KURA-152.1%

Net Income (TTM)

CRVS$-54M

KURA$-297M

FCF (TTM)

CRVS$-45M

KURA$-117M

EPS (TTM)

CRVS-$0.59

KURA-$3.34

ROE (TTM)

CRVS-3615.0%

KURA-20718.0%

ROA (TTM)

CRVS-3362.0%

KURA-4517.0%

ROIC (TTM)

CRVS-3615.0%

KURA-19400.0%

Cash

CRVS$19M

KURA$70M

Debt

CRVS$0

KURA$10M

Net Cash/Debt

CRVS$19M

KURA$60M

Current Ratio (TTM)

CRVS16.16x

KURA4.73x

Quick Ratio (TTM)

CRVS15.92x

KURA4.47x

Debt/Equity (TTM)

CRVS0.00x

KURA0.20x

Debt/Assets (TTM)

CRVS0.0%

KURA0.0%

Interest Coverage (TTM)

CRVSN/A

KURAN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

KURA0.00x

Beta

CRVS1.59

KURA0.53

52W Performance

CRVS50.3%

KURA5.2%

YTD Performance

CRVS43.7%

KURA2.6%

% from 52W High

CRVS-61.0%

KURA-23.7%

% from 52W Low

CRVS64.6%

KURA44.1%

Asset Turnover (TTM)

CRVS0.00x

KURA0.12x

FCF Yield (TTM)

CRVS-5.1%

KURA-12.5%

Earnings Yield (TTM)

CRVS-6.1%

KURA-31.5%

Dividend Yield (TTM)

CRVSN/A

KURAN/A

Rule of 40

CRVS0.0

KURA-159.3

EV/GP/RG

CRVSN/A

KURA0.09

Ticker research

View CRVS research View KURA research

Metric	CRVS Corvus Pharmaceuticals Inc	KURA Kura Oncology Inc
Market & Valuation
Market Cap	$885M	$941M
Enterprise Value	$866M	$881M
Price	$10.52	$10.60
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	12.18x
EV/Sales	0.00x	11.40x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.07x	19.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.14x	-7.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.49x
Revenue & Growth
Revenue (TTM)	$0	$77M
Revenue Growth (YoY)	N/A	-7.3%
Forward Rev Growth	1220.6%	106.3%
Profitability
Gross Margin (TTM)	0.0%	72.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-410.2%
Net Margin (TTM)	0.0%	-384.3%
FCF Margin (TTM)	N/A	-152.1%
Net Income (TTM)	$-54M	$-297M
FCF (TTM)	$-45M	$-117M
EPS (TTM)	-$0.59	-$3.34
ROE (TTM)	-3615.0%	-20718.0%
ROA (TTM)	-3362.0%	-4517.0%
ROIC (TTM)	-3615.0%	-19400.0%
Financial Health
Cash	$19M	$70M
Debt	$0	$10M
Net Cash/Debt	$19M	$60M
Current Ratio (TTM)	16.16x	4.73x
Quick Ratio (TTM)	15.92x	4.47x
Debt/Equity (TTM)	0.00x	0.20x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	0.53
52W Performance	50.3%	5.2%
YTD Performance	43.7%	2.6%
% from 52W High	-61.0%	-23.7%
% from 52W Low	64.6%	44.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.12x
FCF Yield (TTM)	-5.1%	-12.5%
Earnings Yield (TTM)	-6.1%	-31.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-159.3
EV/GP/RG	N/A	0.09
Ticker research	View CRVS research	View KURA research